Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
Jung Eun Lee 2 Articles
Lyn Expression in Osteoblastic Osteosarcoma Tissues and Its Correlation with Clinicopathologic Factors.
Min Sun Jin, Shin Kwang Khang, Min Suk Kim, Hee Seung Choi, Jung Eun Lee, Kil Ho Kim, Dae Geun Jeon, Jae Soo Koh
Korean J Pathol. 2010;44(2):125-131.
DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.2.125
  • 2,821 View
  • 16 Download
  • 2 Citations
AbstractAbstract PDF
BACKGROUND
The Src family kinases (SFKs) are involved in multiple aspects of tumorigenesis, such as, proliferation, migration, and angiogenesis, and are involved in the generation and progression of many types of tumors. Furthermore, dasatinib, a general SFKs inhibitor was recently approved for use in chronic myeloid leukemia. This study was performed to evaluate the expression of Lyn, a member of the SFKs, in osteosarcoma tissues.
METHODS
One hundred and sixteen patients with osteoblastic osteosarcoma were selected for Lyn expression analysis. The correlation between Lyn expression in tumor sections and patients' clinicopathologic characteristics and the prognostic significance of Lyn expression were evaluated.
RESULTS
Lyn was found to be expressed in 52 of the 116 patients (44.8%), and Lyn positive tumor was found to be significantly associated with a lytic tumor pattern on plain radiographs (p = 0.04). Furthermore, those positive for Lyn showed longer metastasis free survival (5-year metastasis free survival, 65.2% for Lyn positive and 46.8% for Lyn negative; p = 0.06), though this was only marginally significant.
CONCLUSIONS
Lyn was found to be overexpressed in osteosarcoma tissues, and this overexpression was found to be correlated with osteolysis.

Citations

Citations to this article as recorded by  
  • Eight Aging-Related Genes Prognostic Signature for Cervical Cancer
    Meilin Yin, Yanhua Weng, Ferenc Olasz
    International Journal of Genomics.2023; 2023: 1.     CrossRef
  • LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
    Yu Jin Kim, Sungyoul Hong, Minjung Sung, Min Jeong Park, Kyungsoo Jung, Ka-Won Noh, Doo-Yi Oh, Mi-Sook Lee, Ensel Oh, Young Kee Shin, Yoon-La Choi
    Oncotarget.2016; 7(50): 82876.     CrossRef
Prognostic Significance of Ezrin Expression in Liposarcoma.
Jae Seok Lee, Min Sun Jin, Jung Eun Lee, Min Suk Kim, Dae Geun Jeon, Jae Soo Koh
Korean J Pathol. 2008;42(5):270-276.
  • 1,524 View
  • 13 Download
AbstractAbstract PDF
BACKGROUND
Ezrin has been reported to be involved in the metastasis of solid tumors in both an animal model and clinical trials. However, questions remains as to whether an ezrin expression is an independent predictor of the event-free survival of liposarcoma patients. METHODS: We analyzed 85 liposarcoma patients without metastasis at the time of presentation. We performed immunohistochemistry with anti-ezrin antibody, and we analyzed the association of an ezrin expression with the clinicopathological variables and event-free survival. RESULTS: Twenty-nine patients (34.1%) showed an ezrin expression. Among the 30 low-grade liposarcoma patients, only one patient showed ezrin positivity. The patients who had an ezrin expression were found to be at a significantly increased risk for metastasis compared with the patients who had no ezrin expression (risk ratio: 3.4, 95% confidence interval: 1.3-9.1). The 10-year metastasis-free survival rate was 26.9% for the patients with an ezrin expression and 86.7% for the patients without an ezrin expression. The ezrin expression rate increased with an advanced tumor grade and stage. CONCLUSION: An ezrin expression is an independent predictor of distant metastasis for liposarcoma. Thus, ezrin has the potential to provide additional prognostic information and to be a novel target for the development of new adjuvant therapies for treating the patients who suffer from liposarcoma.

JPTM : Journal of Pathology and Translational Medicine